ChiCTR2500095144 版本V1.0 版本创建时间2025/01/02 11:53:17 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500095144 

最近更新日期:

Date of Last Refreshed on:

2025-01-02 11:52:56 

注册时间:

Date of Registration:

2025-01-02 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

围术期全脑α相对功率与心脏手术患者术后谵妄的关系:一项前瞻性、观察性临床研究

Public title:

The relationship between perioperative whole brain alpha relative power and postoperative delirium in cardiac surgery patients: a prospective, observational clinical study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

围术期全脑α相对功率与心脏手术患者术后谵妄的关系:一项前瞻性、观察性临床研究

Scientific title:

The relationship between perioperative whole brain alpha relative power and postoperative delirium in cardiac surgery patients: a prospective, observational clinical study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

谭长宽 

研究负责人:

周美艳 

Applicant:

Changkuan Tan 

Study leader:

Meiyan Zhou 

申请注册联系人电话:

Applicant telephone:

+86 137 7593 0827

研究负责人电话:

Study leader's
telephone:

+86 177 1298 8959

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1802237355@qq.com

研究负责人电子邮件:

Study leader's E-mail:

zhoumeiyandoctor@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江苏省徐州市解放南路199号麻醉科

研究负责人通讯地址:

江苏省徐州市解放南路199号麻醉科

Applicant address:

Department of Anesthesiology , 199 Jiefang South Road, Xuzhou, Jiangsu

Study leader's address:

Department of Anesthesiology , 199 Jiefang South Road, Xuzhou, Jiangsu

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

徐州医科大学

Applicant's institution:

Xuzhou Medical University

研究负责人所在单位:

徐州市中心医院

Affiliation of the Leader:

Xuzhou Central Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

XZXY-LK-20240830-0132

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

徐州市中心医院生物医学研究伦理审查委员会

Name of the ethic committee:

Xuzhou Central Hospital Biomedical Research Ethics Review Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2024-08-30 00:00:00

伦理委员会联系人:

侯春艳

Contact Name of the ethic committee:

Chunyan Hou

伦理委员会联系地址:

江苏省徐州市大龙湖街道太行路29号徐州市中心医院新城区门诊3楼伦理委员会办公室

Contact Address of the ethic committee:

Ethics Committee Office, 3rd Floor, Xincheng Outpatient Department, Xuzhou Central Hospital, No. 29 Taihang Road, Dalonghu Street, Xuzhou City, Jiangsu Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 516 8395 6765

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

徐州市中心医院

Primary sponsor:

Xuzhou Central Hospital

研究实施负责(组长)单位地址:

江苏省徐州市解放南路199号麻醉科

Primary sponsor's address:

199 Jiefang South Road, Xuzhou, Jiangsu

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

徐州

Country:

China

Province:

Jiangsu

City:

Xuzhou

单位(医院):

徐州市中心医院

具体地址:

江苏省徐州市解放南路199号

Institution
hospital:

Xuzhou Central Hospital

Address:

199 Jiefang South Road, Xuzhou, Jiangsu

经费或物资来源:

徐州市中心医院

Source(s) of funding:

xuzhou central hospital

研究疾病:

术后谵妄  

Target disease:

postoperative delirium

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

观察全脑围术期的α相对功率是否可以预测心脏手术术后患者谵妄的发生情况,同时探究炎症因子在其中的作用  

Objectives of Study:

Observing the relative power of alpha during the perioperative period of the whole brain can predict the occurrence of delirium in patients undergoing cardiac surgery, while exploring the role of inflammatory factors in it

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

①ASA分级I–III、 ②肝肾功能正常、 ③接受心脏手术

Inclusion criteria

1. ASA grades I-III, 2. normal liver and kidney function, 3 undergoing cardiac surgery

排除标准:

MMSE≤23、BMI>35、术前已存在谵妄、患有精神类或心理疾病、长期服用精神类药物、患有自身免疫性疾病、长期服用非甾体类抗炎药、长期服用糖皮质激素、既往行颅脑手术患者、既往患有脑梗病史、肿瘤病史、二次手术、聋哑人、拒绝签署知情同意书

Exclusion criteria:

MMSE<=23, BMI>35, Preoperative delirium, mental illness or psychological disorders, long-term use of psychotropic drugs, autoimmune diseases, long-term use of nonsteroidal anti-inflammatory drugs, long-term use of glucocorticoids, previous cranial surgery, history of cerebral infarction, history of tumors, secondary surgery, deaf mute person, refusal to sign informed consent form.

研究实施时间:

Study execute time:

From 2024-08-30 00:00:00 To 2026-08-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-09-10 00:00:00 To 2025-12-31 00:00:00

干预措施:

Interventions:

组别:

谵妄

样本量:

90

Group:

delirium

Sample size:

干预措施:

干预措施代码:

Intervention:

nothing

Intervention code:

组别:

非谵妄

样本量:

30

Group:

no delirium

Sample size:

干预措施:

干预措施代码:

Intervention:

nothing

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏 

市(区县):

徐州 

Country:

China

Province:

Jiangsu

City:

Xuzhou

单位(医院):

徐州市中心医院 

单位级别:

三甲 

Institution
hospital:

xuzhou central hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

α相对功率

指标类型:

主要指标

Outcome:

alpha relative power

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

α功率

指标类型:

次要指标

Outcome:

Alpha power

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

爆发抑制比

指标类型:

次要指标

Outcome:

Burst suppression ratio

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 90 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

none

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

共享时间为2025.12.31,方式为临床试验公共管理平台 http://www.medresman.org/uc/index.aspx

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Clinical Trial Public Management Platform http://www.medresman.org/uc/index.aspx The date of disclosing the original data is within three months after the publication of the research results.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-01-02 11:52:56